Pharmaceutical Products M&A Transactions

SERB Pharmaceuticals secures European and MENA rights for Hansa Biopharma's Idefirix® (imlifidase) in a €115M deal, enhancing kidney transplant options.

SERB Pharmaceuticals secures European and MENA rights for Hansa Biopharma's imlifidase, a key therapy for highly sensitized kidney transplant patients, in a €115M deal.

Neurocrine Biosciences strengthens rare disease portfolio with $2.9B acquisition of Soleno Therapeutics and its PWS treatment, VYKAT XR.

EQT AB and IDG Capital are shortlisted to acquire Swiss peptide drug manufacturer PolyPeptide Group, valued at $1.6 billion. Altaris also remains in talks.

Zydus Worldwide DMCC, a Zydus Lifesciences subsidiary, acquires Assertio Holdings for $166.4M in an all-cash transaction, offering a substantial premium.

Cellular Intelligence

Cellular Intelligence acquires Parkinson's cell therapy rights from Novo Nordisk, leveraging AI for faster development and manufacturing. Backed by Khosla Ventures, CZI, SciFi VC, AMD Ventures.

Bayer's $2.45B acquisition of Perfuse Therapeutics bolsters its ophthalmology pipeline with a novel treatment for glaucoma and diabetic retinopathy.

Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1B, significantly expanding its U.S. rare disease and neurological disorder footprint.

Aurica Search Fund I completes its fifth investment with the acquisition of Super's Diana, a Spanish animal health company, via Rigi Capital Partners.

Rigi Capital acquires Super's Diana, a Catalan animal health company, with support from Aurica Search Fund. Details on deal and market impact.

Merck strengthens its oncology pipeline by acquiring Terns Pharmaceuticals for $5.8 billion, adding a promising CML treatment candidate.